Attenuated plasmodium with deactivated HMGB2 gene, as vaccine

A technology of Plasmodium and Plasmodium falciparum, which is applied in the field of medicine and can solve the problems that the efficacy and harmlessness of vaccines have yet to be confirmed.

Inactive Publication Date: 2014-06-04
UNIV PARIS 6 PIERRE & MARIE CURIE +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the efficacy and harmlessness of vaccines using these genetically attenuated live parasites remains to be established

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Attenuated plasmodium with deactivated HMGB2 gene, as vaccine
  • Attenuated plasmodium with deactivated HMGB2 gene, as vaccine
  • Attenuated plasmodium with deactivated HMGB2 gene, as vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0109] While investigating the function of HMGB proteins, the inventors recently discovered that the HMGB2 protein of Plasmodium berghei is involved in experimental cerebral malaria (NPE ) establishment. Inactivation of the hmgb2 gene in PbANKA did not impede parasite development in C57BL / 6 mice, but induced a delay in NPE establishment and even completely abolished NPE establishment in 65% of cases. Furthermore, it has been shown that administration of recombinant HMGB2 protein to mice previously infected with PbANKA Δhmgb2 can restore the development of cerebral malaria.

[0110] Materials and methods

[0111] mouse

[0112] The mice used were C57BL / 6 mice (Charles River Laboratories). These mice were susceptible to experimental cerebral malaria (NP-S).

[0113] wild type parasite

[0114] Plasmodium berghei ANKA parasite (PbANKA) (MRA-867) induced death in C57BL / 6 mice due to cerebral malaria at 7 days + / - 1 . This parasite has a GFP tag under the control of the eef1 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to novel compositions and methods for immunizing a host against malaria using a Plasmodium parasite which has been genetically attenuated by inactivating the function of the hmgb2 gene.

Description

technical field [0001] The invention belongs to the field of medicine, especially malaria prevention and treatment. Background technique [0002] Malaria is an infectious disease caused by eukaryotic unicellular parasites of the Plasmodium genus. Such parasitic diseases occur all over the world and cause serious economic and health problems in developing countries. Plasmodium falciparum (P.falciparum) is the most harmful species among the five types of Plasmodium that infects humans. According to the World Health Organization (abbreviated in French as OMS), Plasmodium falciparum causes 250 to 500 million cases of acute illness and about 1 million deaths per year (especially in children younger than 5 years and pregnant women). Cerebral malaria is a serious neurological complication of malaria responsible for the vast majority of deaths from the disease. Even if the individual survives, cerebral malaria can cause severe neurologic side effects, especially in young children...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P33/06A61K39/015
CPCA61K35/76A61K2039/522A61K39/015C07K14/445A61P33/06A61P37/04Y02A50/30
Inventor 凯瑟琳·瓦克罗西尔维·布里凯纳杜·埃塞尼亚·劳森-赫巴恩萨拉赫迪内·梅凯里罗伯特·梅纳德
Owner UNIV PARIS 6 PIERRE & MARIE CURIE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap